New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer)
References
1. Coleman CI, Antz M, Simard E, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Oral Presentation at ECAS 2016. 17 April 2016.
2. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New Eng J Med 2011;365:883-91.
Review
For citations:
New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer). Rational Pharmacotherapy in Cardiology. 2016;12(4):487-488. (In Russ.)
Views: 337
Email this article 